Pulse wave reflection is amplified in normotensive patients with autosomal-dominant polycystic kidney disease and normal renal function

American Journal of Nephrology

Volumn 27, Issue 3, 2007, Pages 240-246

  Borresen, Malene L ^a,c   Wang, Dan ^b   Strandgaard, Svend ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b GEORGETOWN UNIVERSITY   (United States)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

Augmentation index; Autosomal dominant polycystic disease; Endothelial dysfunction; Pulse wave analysis; Pulse wave velocity

Indexed keywords

ADULT; AORTA PRESSURE; ARTERY; ARTICLE; BLOOD PRESSURE; BRACHIAL ARTERY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; EQUIPMENT; FEMALE; GLOMERULUS FILTRATION RATE; HEART RATE; HUMAN; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; MALE; MEASUREMENT; MULTIPLE LINEAR REGRESSION ANALYSIS; PATHOLOGY; PLASMA CLEARANCE; PRIORITY JOURNAL; PULSE WAVE; STATISTICAL ANALYSIS; STUDENT T TEST; SYSTOLIC BLOOD PRESSURE; TONOMETRY; CASE CONTROL STUDY; KIDNEY; MANOMETRY; PATHOPHYSIOLOGY; PHYSIOLOGY; PULSE RATE; VASODILATATION;

ADULT; ARTERIES; CASE-CONTROL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MALE; MANOMETRY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PULSE; VASODILATION;

EID: 34250854549     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000101369     Document Type: Article

References (28)

1. Gabow PA: Autosomal dominant polycystic kidney disease. N Engl J Med 1993;329:332-342.
2. Wang D, Iversen J, Strandgaard S: Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000;11:1371-1376.
3. Wang D, Iversen J, Wilcox CS, Strandgaard S: Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 2003;64:1381-1388.
4. Clausen P, Feldt-Rasmussen B, Iversen J, Lange M, Eidemak I, Strandgaard S: Flow-associated dilatory capacity of the brachial artery is intact in early autosomal dominant polycystic kidney disease. Am J Nephrol 2006;26:335-339.
5. Shiburi CP, Staessen JA, Maseko M, Wojciechowska W, Thijs L, Van Bortel LM, Woodiwiss AJ, Norton GR: Reference values for SphygmoCor measurements in South Africans of African ancestry. Am J Hypertens 2006;19:40-46.
6. Frimodt-Moller M, Nielsen AH, Kamper AL, Strandgaard S: Pulse-wave morphology and pulse-wave velocity in healthy human volunteers: examination conditions. Scand J Clin Lab Invest 2006;66:385-394.
7. O'Rourke MF, Pauca A, Jiang XJ: Pulse wave analysis. Br J Clin Pharmacol 2001;51:507-522.
8. Pauca AL, O'Rourke MF, Kon ND: Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension 2001;38:932-937.
9. Soderstrom S, Nyberg G, O'Rourke MF, Sellgren J, Ponten J: Can a clinically useful aortic pressure wave be derived from a radial pressure wave? Br J Anaesth 2002;88:481-488.
10. Gallagher D, Adji A, O'Rourke MF: Validation of the transfer function technique for generating central from peripheral upper limb pressure waveform. Am J Hypertens 2004;17:1059-1067.
11. Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ: The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol 2000;525:263-270.
12. Chiu YC, Arand PW, Shroff SG, Feldman T, Carroll JD: Determination of pulse wave velocities with computerized algorithms. Am Heart J 1991;121:1460-1470.
13. Martensson J, Groth S, Rehling M, Gref M: Chromium-51-EDTA clearance in adults with a single-plasma sample. J Nucl Med 1998;39:2131-2137.
14. McEniery CM, Yasmin, Hall IR, Qasem A, Wilkinson IB, Cockcroft JR: Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol 2005;46:1753-1760.
15. London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME: Arterial wave reflections and survival in end-stage renal failure. Hypertension 2001;38:434-438.
16. van Trijp MJ, Bos WJ, Uiterwaal CS, Oren A, Vos LE, Grobbee DE, Bots ML: Determinants of augmentation index in young men: the ARYA study. Eur J Clin Invest 2004;34:825-830.
17. Blacher J, Safar ME, Guerin AP, Pannier B, Marchais SJ, London GM: Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 2003;63:1852-1860.
18. Wang D, Iversen J, Strandgaard S: Contractility and endothelium-dependent relaxation of resistance vessels in polycystic kidney disease rats. J Vasc Res 1999;36:502-509.
19. Merta M, Reiterova J, Rysava R, Tesar V, Zavada J, Jachymova M, Zima T: Role of endothelin and nitric oxide in the pathogenesis of arterial hypertension in autosomal dominant polycystic kidney disease. Physiol Res 2003;52:433-437.
20. Clausen P, Feldt-Rasmussen B, Iversen J, Lange M, Eidemak I, Strandgaard S: Flow-associated dilatory capacity of the brachial artery is intact in early autosomal dominant polycystic kidney disease. Am J Nephrol 2006;26:335-339.
21. Hadimeri H, Lamm C, Nyberg G: Coronary aneurysms in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1998;9:837-841.
22. Wang D, Braendstrup O, Larsen S, Horn T, Strandgaard S: The expression and activity of renal nitric oxide synthase and circulating nitric oxide in polycystic kidney disease rats. APMIS 2004;112:358-368.
23. Al-Nimri MA, Komers R, Oyama TT, Subramanya AR, Lindsley JN, Anderson S: Endothelial-derived vasoactive mediators in polycystic kidney disease. Kidney Int 2003;63:1776-1784.
24. Persu A, Stoenoiu MS, Messiaen T, Davila S, Robino C, El-Khattabi O, Mourad M, Horie S, Feron O, Balligand JL, Wattiez R, Pirson Y, Chauveau D, Lens XM, Devuyst O: Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum Mol Genet 2002;11:229-241.
25. Walker D, Consugar M, Slezak J, Rossetti S, Torres VE, Winearls CG, Harris PC: The ENOS polymorphism is not associated with severity of renal disease in polycystic kidney disease 1. Am J Kidney Dis 2003;41:90-94.
26. Woo DD, Miao SY, Pelayo JC, Woolf AS: Taxol inhibits progression of congenital polycystic kidney disease. Nature 1994;368:750-753.
27. Woo DD, Tabancay AP Jr, Wang CJ: Microtubule active taxanes inhibit polycystic kidney disease progression in cpk mice. Kidney Int 1997;51:1613-1618.
28. Jafar TH, Stark PC, Schmid CH, Strandgaard S, Kamper AL, Maschio G, Becker G, Perrone RD, Levey AS: The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int 2005;67:265-271.